Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non–Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09

Oliver Gautschi(Université Toulouse III - Paul Sabatier), Adrian F. Ochsenbein(University of Bern), Sacha I. Rothschild(University Hospital of Basel), Daniel Rauch(Washington University in St. Louis), Miklos Pless(Ontario Institute for Cancer Research), Rolf A. Stahel(International Breast Cancer Study Group), Jonas Feilchenfeldt(Hôpital du Valais), Rolf Jaggi(University of Bern), Martin Früh(University of Bern), Martin Brutsche(University of Basel), Nicholas Mach, Richard Cathomas(Kantonsspital Graubünden), Elisabeth Oppliger Leibundgut(University Hospital of Bern), Christiane Pilop(University of Zurich), Lukas Stalder(Swiss Group For Clinical Cancer Research), Solange Peters(University Hospital of Lausanne), Alfred Zippelius(University of Basel), Carlo R. Largiadèr(University of Bern), Qiyu Li(Army Medical University), Lukas Bubendorf(University of Basel), Spasenija Savic(University Hospital of Basel), Daniel Betticher
Clinical Lung Cancer
March 5, 2015
10.1016/j.cllc.2015.02.007
Cited by 15

Related Papers

Tissue microarrays for high-throughput molecular profiling of tumor specimens
|Nature Medicine|1998|4.1k
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.4k
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
|Annals of Oncology|2018|2.9k
Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2017|2.4k
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
|Journal of Clinical Oncology|2004|2.4k